John G Gerber
Affiliation: University of Colorado Health Sciences Center
- Lack of an effect of age on beta-adrenoceptor-mediated lipolysis in isolated human adipocytesJ G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
J Gerontol A Biol Sci Med Sci 54:B71-7. 1999..These data suggest that neither beta 1- nor beta 2-adrenoceptor responses in human adipocytes show significant changes due to aging...
- Therapeutic drug monitoring in the treatment of HIV-infectionJohn G Gerber
Divisions of Clinical Pharmacology and Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Clin Virol 27:117-28. 2003..At this point in time we consider TDM in the treatment of HIV-infection as experimental with significant promise for the future...
- Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber
University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Acquir Immune Defic Syndr 39:307-12. 2005..The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA...
- Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401J G Gerber
University of Colorado Health Sciences Center, 4200 E 9th Avenue, Denver, CO 80262, USA
J Acquir Immune Defic Syndr 27:153-60. 2001..The effect of ritonavir 400 mg/saquinavir 400 mg twice daily on the stereoselective pharmacokinetics of methadone was examined in 12 HIV-infected, methadone-using study subjects...
- Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19John G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Chirality 16:36-44. 2004....
- Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunctionDavid L Wyles
Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
Clin Infect Dis 40:174-81. 2005....
- Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteersJennifer J Kiser
Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
J Acquir Immune Defic Syndr 47:570-8. 2008..Tolerability and lipid changes were also assessed...
- Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
J Acquir Immune Defic Syndr 47:459-66. 2008..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
- Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser
Division of Clinical Pharmacology, University of Colorado Health Science Center, Denver, CO 80262, USA
Curr HIV/AIDS Rep 2:61-7. 2005..Nevertheless, there are specific clinical instances where this experimental intervention should be considered to potentially reduce toxicity and improve therapeutic outcomes...
- Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substratesShahrzad Dilmaghanian
Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, Colorado, USA
Chirality 16:79-85. 2004..Overall, levo-KTZ was 2-4-fold more active than dextro-KTZ. Therefore, levo-KTZ is a more potent inhibitor of CYP3A4 and has stronger in vitro antifungal activity. Chirality 16:79-85, 2004...
- Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavirDavid W Haas
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Acquir Immune Defic Syndr 50:290-3. 2009..Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P4503A by rifampin markedly lowers HIV protease inhibitor plasma concentrations...
- Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047Carl J Fichtenbaum
University of Cincinnati College of Medicine, Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, Ohio 45267-0405, USA
AIDS 16:569-77. 2002..Dose adjustment of pravastatin may be necessary with concomitant use of RTV and SQVsgc. Pravastatin does not alter the NFV pharmacokinetics, and thus appears to be safe for concomitant use...
- Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum
Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Clin Pharmacokinet 41:1195-211. 2002....
- Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta
University of Alabama at Birmingham, Birmingham, Alabama, USA
Antimicrob Agents Chemother 51:3104-10. 2007..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
- Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta
Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 18:825-34. 2002..This position paper offers guidelines to aid clinicians who choose to incorporate TDM into the routine care of their patients...
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108Judith A Aberg
New York University, New York, New York, USA
AIDS 20:725-9. 2006..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
- Protein binding in antiretroviral therapiesMarta Boffito
St. Stephens Centre, Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom
AIDS Res Hum Retroviruses 19:825-35. 2003....
- Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
J Pharmacokinet Pharmacodyn 33:399-419. 2006..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
- Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)Barbara M Gripshover
University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
Antivir Ther 11:619-23. 2006..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses...
- The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira
Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
J Infect Dis 186:198-204. 2002..The antiretroviral effect of APV monotherapy was related to APV concentrations...
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Pharmacol Ther 78:143-53. 2005..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
- The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back
Department of Pharmacology, University of Liverpool, Liverpool, UK
J Acquir Immune Defic Syndr 39:S1-23, quiz S24-25. 2005....
- Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistanceHulin Wu
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
J Acquir Immune Defic Syndr 39:272-83. 2005..The proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients...
- Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapyJennifer R King
University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
AIDS 19:1059-63. 2005..These data suggest that RTV affects IDV protein-binding characteristics and IDV also exhibits concentration dependent binding when administered with RTV...
- Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroismDavid Dunmire
Department of Chemistry, Syracuse University, Syracuse, New York 13244-4100, USA
Chirality 17:S101-8. 2005....
- Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan
University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
J Acquir Immune Defic Syndr 31:257-75. 2002..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
- Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicityMarshall J Glesby
AIDS Read 13:346-7. 2003
- Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta
Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
J Acquir Immune Defic Syndr 37:1358-66. 2004....
- Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult Michael P Dube
Indiana University, Indianapolis, USA
Clin Infect Dis 37:613-27. 2003
- Abacavir pharmacokinetics in hepatic dysfunctionDavid L Wyles
Clin Infect Dis 40:909-10. 2005